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Basic estrogen receptor (ER) molecule (vero-ER) of porcine uterus, which was previously shown to be the 
activated ER necessary to translocate from the cytoplasm into the nucleus, possesses a strongly 
hydrophobic nature. The strong hydrophobicity of vero-ER was concealed through binding with ER- 
binding factors (ERBFs). Vera-ER lost its strong hydrophobicity and its capability to bind with ERBFs 
after limited proteolysis by endogenous protease. The strong hydrophobic domain of vero-ER, 
indispensable for the nuclear translocation, was assumed to be located near the binding site with ERBFs. 
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1. INTRODUCTION 
Steroid hormone receptors are extremely suscep- 
tible to modifications by the proteases present in 
the target tissues [l-3]. By utilizing antipain [4], a 
protease inhibitor of microbial origin, we showed 
previously that there is one basic estrogen receptor 
(ER) molecule (vero-ER) (Mr 82000) in the 
estrogen target tissues [5,6]. Vera-ER interacted 
specifically with the endogenous protein com- 
ponents designated as ER-binding factors (ERBFs) 
[‘5S’ ER-forming factor (‘5s’ ER-FF), (compo- 
nent A, M, 58000); ‘6s’ ER-FF, (component B, M, 
13 7OO)e; ‘7s’ ER-FF, (component B)z - (component 
A); ‘8s’ ER-FF, (component B)6 - (component A)] 
to form ERs [‘5S’ ER, (vero-ER) - (component A); 
Abbreviations: ER, estrogen receptor; ERBF, estrogen 
receptor-binding factor; ‘5s’ ER-FF, ‘5s’ estrogen 
receptor-forming factor; TEMA buffer, 10 mM 
Tris-HCl, 1.5 mM EDTA, 1.5 mM 2-mercaptoethanol, 
0.25 mM antipain, pH 8.0 at 2°C 
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‘6s’ ER, (vero-ER) - (component B)6; ‘7s’ ER, 
(vero-ER) - (component B)2 - (component A); ‘8s’ 
ER, (vero-ER) - (component B)6 - (component A)] 
with various molecular constitutions [6-81 (fig. 1). 
Steroid hormone receptor in the cytoplasm 
undergoes activation to acquire the capability to 
translocate into the nucleus [9-121. It was 
previously shown that under activation conditions 
of the cytoplasmic ER, vero-ER is dissociated 
from its original binding with ERBFs [8,13]. Vero- 
ER was shown to be the activate ER necessary to 
translocate from the cytoplasm into the nucleus 
[13,14]. It was recently proposed that a similar 
molecular mechanism may be applicable also for 
the activation of the glucocorticoid receptor [ 151. 
We report here that vero-ER possesses an extreme- 
ly hydrophobic domain, which is concealed 
through binding with ERBFs. 
2. MATERIALS AND METHODS 
Antipain was purchased from Protein Research 
Foundation (Osaka). [2,4,6,7,16,17-3H]Estradiol- 
17,& (147 Ci/mmol) ( [3H]estradiol) was purchased 
PubliXhed by Elsevier Science Publishers B. V. 
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Fig. 1. Uterine vero-ER, ERBFs and the complexes [6,8]. 
from Amersham International (England). Phenyl- 
Sepharose CL-4B was from Pharmacia (Uppsala). 
Cytosol was prepared from fresh porcine uteri in 
TElvIA buffer (10 ml’@ Tris-HCl, 1.5 mM EDTA, 
1.5 mM Z-mercaptoethanol, 0.25 mM antipain, 
pH 8.0 at 2°C) and labeled with [3H]estradiol as in 
[5]. Vera-ER (sedimentation coefficient 4.5 S; 
Stokes radius 44 A) freed from ERBFs was prepa- 
red from the labeled cytosol as in [5] by a two-step 
gel filtration on Sephadex G-150 columns carried 
out in TEMA buffer in the presence of 0.4 M KCl, 
and then in the presence of 0.4 M NaSCN. Partial 
proteolysis of vero-ER into secto-ER (sedimenta- 
tion coefficient 4.5 S; Stokes radius 35 A) or 
‘3.8s’ ER (sedimentation coefficient 3.8 S; Stokes 
256 
radius 32 A) by the endogenous protease was car- 
ried out as in [5,6]. Partially purified ‘5s’ ER-FF, 
‘6s’ ER-FF and ‘8s’ ER-FF were prepared from 
the cytosol of porcine uterus as in [6,7]. Recon- 
structed ‘5s’ ER, ‘6s’ ER and ‘8s’ ER were 
prepared from vero-ER and the corresponding 
ERBFs (‘5s’ ER-FF, ‘6s’ ER-FF and ‘8s’ ER-FF) 
as in [6,7]. Sucrose density gradient centrifugation 
of ERs was carried out in 5-20% sucrose gradients 
in TEMA buffer as in 151. 
3. RESULTS AND DISCUSSION 
We showed previously that vero-ER of the 
uterine cytosol is dissociated from ERBFs in high- 
salt (0.4 M KCl) conditions, but is complexed with 
‘8s’ ER-FF in low-salt conditions [6-81. ER of the 
cytosol of porcine uterus sedimented at 8 S in 
TEMA buffer, and at 4.5 S in TEMA buffer con- 
taining 0.4 M KC1 (fig.2A). When the ER of the 
uterine cytosol labeled with [3H]estradiol was ap- 
FRACTION NUMBER 
Fig.2. Sedimentation analysis of cytosolic and 
reconstructed ERs. (A) The cytosolic ER and the 
proteolyzed ERs were analyzed by sucrose density 
gradient centrifugation i TEMA buffer in the presence 
or absence of 0.4 M KCl. Labeled cytosol in TEMA 
buffer (-o-); labeled cytosol in TEMA buffer 
containing 0.4 M KC1 (-G-); s&o-ER in TEMA 
buffer {---Cl---); ‘3.85’ ER in TEMA buffer (---A---). 
(B) Reconstructed ERs were analyzed by sucrose density 
gradient centrifugation in TEMA buffer. Vera-ER 
(--G--); reconstructed ‘5s’ ER (-t-); reconstructed 
‘6s’ ER (+); reconstructed ‘8s’ ER (--o-). The 
arrows mark the peak of [14C]BSA (4.6 S) as an internal 
marker. 
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plied to a phenyl-Sepharose column in TEMA buf- 
fer in the presence of 0.4 M KCl, ER was attached 
to the column (8 x ld cpm ER/ml phenyl- 
Sepharose). The attached ER could not be eluted 
from the column with TEMA buffer. However, 
when the ER of the uterine cytosol labeled with 
[3H]estradiol was applied to a phenyl-Sepharose 
column in the absence of KCl, ER passed straight 
through the column. The results seemed to suggest 
the presence of a strong hydrophobic domain in 
vero-ER, which is concealed through binding with 
‘8s’ ER-FF. Accordingly, we analyzed in detail the 
hydrophobicity of vero-ER freed from ERBFs and 
the ERs reconstructed from vero-ER and ERBFs. 
In fig.2B are shown the sedimentation patterns of 
vero-ER and the reconstructed ERs. Vera-ER 
freed from ERBFs was attached to the phenyl- 
Sepharose column when applied under the low-salt 
conditions (TEMA buffer ) (fig.3A). The attached 
vero-ER could not be eluted even with TEMA buf- 
fer containing 50% ethylene glycol. To elute vero- 
ER from the column, it was necessary to utilize 
ethanol as a polarity-reducing agent. Vera-ER 
could be eluted quantitatively from the column 
with TEMA buffer containing 30% ethanol 
(fig.3A). [3H]Estradiol activity of the eluate did 
not diminish throug the dialysis against TEMA 
buffer, indicating that the dissociation of 
[3H]estradiol from the receptor during the elution 
process was negligible. These results demonstrated 
the extremely strong hydrophobicity of vero-ER. 
In contrast, reconstructed ‘5s’ ER, ‘6s’ ER and 
‘8s’ ER passed straight through the phenyl- 
Sepharose column when applied in TEMA buffer 
(fig.3B). This indicated that the strong 
hydrophobic domain of vero-ER is concealed 
through binding with ERBFs. The results also sug- 
gested that the hydrophobic domain of vero-ER is 
located near the binding site with ERBFs. 
We reported previously that the binding site of 
vero-ER with ERBFs is easily proteolyzed by en- 
dogenous proteases [1,5,6]. The proteolyzed ERs 
[se&o-ER (k& 65 000); ‘3.8s’ ER (Mr SOOOO)] did 
no longer interact with ERBFs [ 1,5,6], and did not 
translocate into the nucleus [14]. Both se&o-ER 
and ‘3.8s’ ER passed straight through the phenyl- 
Sepharose column under the low-salt conditions 
(fig.3C), indicating that the strongly hydrophobic 
domain is removed by limited proteolysis of vero- 
ER. These observations also supported the 
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Fig.3. Analysis of the hydrophobicity of vero-ER, the 
complexes of vero-ER with ERBFs and the proteolyzed 
ERs with a phenyl-Sepharose column. 4 x 10’ cpm of 
ERs in 2 ml of TEMA buffer were applied (beginning at 
the first arrow) to 0.5 ml (0.9 x 0.8 cm) columns pre- 
equilibrated with TEMA buffer. The columns were then 
washed 7-times with 2 ml TEMA buffer, and 
subsequently 7-times with 2 ml TEMA buffer containing 
50% ethylene glycol (beginning at the second arrow). 
The columns were finally washed 7-times with 2 ml of 
TEMA buffer containing 30% ethanol (beginning at the 
third arrow), The ER activities of the eluates are 
expressed as % of the total amount applied: (A) vero-ER 
(u); (B) reconstructed ‘5s ER (b); 
reconstructed ‘6s’ ER (-A-); reconstructed ‘8s’ ER 
(-o-); (C) secfo-ER (---•---); ‘3.W ER (---A---). 
assumption that the binding site of vero-ER with 
ERBFs and the strongly hydrophobic domain are 
situated in sterically close proximity. 
We showed previously that vero-ER translocates 
from the cytoplasm into the nucleus without suf- 
fering any proteolysis [ 161. The strongly 
hydrophobic domain of vero-ER is expected to 
play indispensable roles in the subsequent reac- 
tions of the receptor in the nucleus to trigger the 
biological response of the target cell. 
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